Moreover, treatment with the HDACi VPA and LBH589 caused a comparable and dose-dependent decrease of MYB and SKI protein levels, which may have a therapeutic impact for AML patients with both increased MYB and SKI levels. This evidence concerns the gene SKI and acute myeloid leukemia.